(12) **Translation of European patent specification**

(11) **NO/EP 3307734 B1**

(19) NO

NORWAY

(51) Int Cl.

C07D 405/14 (2006.01)
A61K 31/404 (2006.01)
A61K 31/416 (2006.01)
A61P 29/00 (2006.01)
A61P 37/00 (2006.01)
C07D 209/14 (2006.01)
C07D 209/18 (2006.01)
C07D 235/16 (2006.01)
C07D 401/10 (2006.01)
C07D 403/10 (2006.01)
C07D 405/10 (2006.01)
C07D 471/04 (2006.01)
C07D 487/04 (2006.01)
C07D 491/10 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2020.03.23
(80)	Date of The European Patent Office Publication of the Granted Patent	2019.11.27
(86)	European Application Nr.	16731721.3
(86)	European Filing Date	2016.06.08
(87)	The European Application's Publication Date	2018.04.18
(30)	Priority	2015.11.20, US, 201562257806 P 2016.06.01, US, 201662343905 P 2015.06.09, WO, PCT/IB15/001693
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
	Designated Extension States:	BA ; ME
	Designated Validation States:	MA; MD
(73)	Proprietor	AbbVie Inc., 1 North Waukegan Road, North Chicago, IL 60064, USA
(72)	Inventor	ARGIRIADI, Maria, A., 15 Sadie Hutt Lane, Southborough, MA 01772, USA BREINLINGER, Eric, C., 54 Hanson Road, Charlton, MA 01507, USA CUSACK, Kevin, P., 115 Jennifer Drive, Holden, MA 01520, USA HOBSON, Adrian, D., 25 Holman Street, Shrewsbury, MA 01545, USA POTIN, Dominique, 23 Chemin de Daix, 21240 Talant, Frankrike BARTH, Martine, 20 rue Claude deschault, 21380 Asnières les Dijon, Frankrike AMAUDRUT, Jérôme, 30 boulevard Rembrandt, 21000 Dijon, Frankrike

POUPARDIN, Olivia, 11 promenade du fort, 21490 Varios et Chaignot, Frankrike
MOUNIER, Laurent, 3 Route de Savigny, 21380 Marsannay le Bois, Frankrike
KORT, Michael, E., 507 Green Avenue, Lake Bluff, IL 60044, USA

(74) Agent or Attorney CURO AS, Vestre Rosten 81, 7075 TILLER, Norge

---

(54) Title **NUCLEAR RECEPTOR MODULATORS (ROR) FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES**

(56) References Cited:
WO-A1-2012/076672
WO-A1-2012/106995
WO-A1-2014/026328
WO-A1-2015/036411
BENJAMIN P. FAUBER ET AL: "Modulators of the Nuclear Receptor Retinoic Acid Receptor-Related Orphan Receptor-[gamma] (ROR[gamma] or RORc)", JOURNAL OF MEDICINAL CHEMISTRY, vol. 57, no. 14, 24 July 2014 (2014-07-24) , pages 5871-5892, XP055242989, US ISSN: 0022-2623, DOI: 10.1021/jm401901d

Patentkrav

1. Forbindelse med formel (I-a):



(I-a),

eller et farmasøytisk akseptabelt salt av samme, hvori:

G og J er uavhengig CH eller N;

W er C eller CR^a, L^1 er forbundet med W eller Y; og

A og E er uavhengig C eller N forutsatt at begge ikke er N;

V er CR^3 eller N;

X er CR^a, NR^a, N eller O;

Y er C, CR^a, NR^a, N, O eller S;

Z er CR^3 eller N; eller

W er N eller NR^a, L^1 er forbundet med W eller Y; og

A og E er uavhengig C eller N forutsatt at begge ikke er N;

V er CR^3 eller N;

X er CR^a, NR^a eller N;

Y er C, CR^a eller N;

Z er CR^3 eller N; eller

L^1 er $-CH_2-$ eller -C(O)-;

L^2 er -C(O)-;

R^1 og R^2 er uavhengig halogen, $-O-(C_1-C_3)$alkyl, syklopropyl, eller (C_1-C_3)alkyl;

hver R^3 er uavhengig H, $-CF_3$, -CN, halogen, $-OCHF_2$, $-OCF_3$, $-C(O)N(R^e)_2$, $-NR^eCOR^e$, $-(C_1-C_3)$alkyl, $-O-(C_1-C_3)$alkyl, $-S-(C_1-C_3)$alkyl, (C_3-C_6)sykloalkyl, eller morfolinyl;

R^4 er (C_1-C_6)alkyl valgfritt substituert med én eller flere substituenter uavhengig valgt fra halo, -CO_2H, og -CO_2(C_1-C_4)alkyl; eller

R^4 er -NH-CH_2-tetrahydro-2H-pyranyl valgfritt substituert med én eller to substituenter uavhengig valgt fra -OH og -O(C_1-C_4)alkyl; eller

R^4 er -N(H)-(C_3-C_6)sykloalkyl valgfritt substituert med én eller flere substituenter uavhengig valgt fra F, -OH, -COOH, og -CO_2(C_1-C_4)alkyl; eller

R^4 er (C_3-C_6)sykloalkyl valgfritt substituert med én eller flere substituenter uavhengig valgt fra F, -OH, -COOH, og -CO_2(C_1-C_4)alkyl; eller

R^4 er azabisyklo[2,2,1]heptanyl eller azabisyklo[3,1,0]heksanyl, hver valgfritt substituert med - CO_2H eller -CO_2(C_1-C_4)alkyl; eller

R^4 er azaspiro[3,3]heptanyl valgfritt substituert med -CH_2CO_2H, -$CH_2CO_2CH_3$, -CO_2H, -CO_2CH_3; eller

R^4 er 2-oxa-6-azaspiro[3,3]heptanyl, 2-oxa-7-azaspiro[3,5]nonanyl, eller 2-oxa-8-azaspiro[4,5]dekanyl, hver valgfritt substituert med -CH_2CO_2H; eller

R^4 er azetidinyl valgfritt substituert med én eller to substituenter uavhengig valgt fra - CH_3, -OH, -OCH_3, -(C_1-C_4)alkylen-OH, -CH_2OCH_3, -(C_1-C_4)alkylenO(C_1-C_4)alkyl, -CO_2(C_1-C_4)alkyl, -CO_2H, -(C_1-C_4)alkylen-CO_2H, -(C_1-C_4)alkylen-CO_2-(C_1-C_4)alkyl, -$N(CH_3)_2$, og pyrrolidinylgrupper; eller

R^4 er 1 2-diazepanyl eller 1 4-diazepanyl, hver valgfritt substituert med -(C_1-C_4)alkylen-OH; eller

R^4 er morfolinyl valgfritt substituert med =O; eller

R^4 er piperazinyl, piperidinyl, eller pyrrolidinyl, hver valgfritt substituert med én eller flere substituenter uavhengig valgt fra -halo, -CN, -(C_1-C_4)alkyl, -CH_2-syklopropyl, -(C_1-C_4)alkylen-F, -CF_3, -CH_2CF_3, -COOH, -(C_1-C_4)alkylenCOOH, -$CH(OH)CO_2H$, -$COCH_3$, -CO_2(C_1-C_4)alkyl, -$CH(OH)CO_2CH_3$, -(C_1-C_4)alkylen-C(=O)O(C_1-C_4)alkyl, -(C_1-C_4)alkylen-OH, -OH, -O(C_1-C_4)alkyl, -(C_1-C_4)alkylenO(C_1-C_4)alkyl, -O(C_1-C_4)alkylenCO_2H, -O(C_1-C_4)alkylenC(=O)O(C_1-C_4)alkyl, -$CONHCH_3$, -SO_2-(C_1-C_4)alkyl, -NH_2, -NH(C_1-C_4)alkyl, -N((C_1-C_4)alkyl)$_2$, syklobutankarboksylsyre, og oksetanyl;

hver R^a er uavhengig H, -C(O)CH_3, valgfritt substituert (C_1-C_6)alkyl, valgfritt substituert (C_3-C_6)sykloalkyl eller -S(O)$_2$-fenyl; og

R^e er uavhengig H eller -(C_1-C_3)alkyl;

forutsatt at ikke flere enn to av A, E, W, X og Y er N.

2. Forbindelse ifølge krav 1, eller et farmasøytisk akseptabelt salt av samme, hvori R^1 og R^2 begge er halo eller $-CH_3$.

3. Forbindelse ifølge ett av kravene 1 eller 2, eller et farmasøytisk akseptabelt salt av samme, hvori W er C eller CH, A er C, og E er C.

4. Forbindelse ifølge ett av kravene 1 til 3, eller et farmasøytisk akseptabelt salt av samme, hvori G er CH.

5. Forbindelse ifølge ett av kravene 1 til 4, eller et farmasøytisk akseptabelt salt av samme, hvori J er CH.

6. Forbindelse ifølge krav 1, eller et farmasøytisk akseptabelt salt av samme, hvori:

W er CH;

X er CR^a, hvori R^a er H eller $-CH_3$;

Y er N;

A er C;

E er C;

V er CR^3, hvori R^3 er H;

Z er N eller CR^3, hvori R^3 er H, $-CH_3$, eller $-CF_3$;

L^1 er forbundet med Y;

L^1 er $-CH_2-$ eller -C(O)-;

L^2 er -C(O)-;

R^1 er -Cl eller $-CH_3$;

R^2 er -Cl eller $-CH_3$;

hver R^3 er uavhengig H, -F, -Cl, -CN, $-CH_3$, $-CH(CH_3)_2$, $-CF_3$, $-OCHF_2$, $-OCF_3$, $-SCH_3$, eller syklopropyl; og

R^4 er valgfritt substituert 2-oxa-6-azaspiro[3,3]heptanyl eller valgfritt substituert piperidinyl.

7. Forbindelse ifølge krav 6, eller et farmasøytisk akseptabelt salt av samme, hvori det valgfritt substituerte piperidinyl er valgfritt substituert med $-CH_3$, -COOH, $-CH_2CO_2H$, $-CH_2CH_2CO_2H$, $-CO_2CH_3$, $-CO_2CH_2CH_3$, eller -OH.

8. Forbindelse ifølge krav 1, eller et farmasøytisk akseptabelt salt av samme, hvori:

W er C;

X er NR^a, hvori R^a er H, $-CH_3$, $-CH_2CH_3$, $-COCH_3$, eller $-CH_2CH(CH_3)_2$;

Y er CR^a, hvori R^a er H;

Z er CR^3, hvori R^3 er H eller $-CH_3$;

A er C;

E er C;

V er CR^3, hvori R^3 er H, -CN, $-CH_3$, eller $-CF_3$;

L^1 er forbundet med W;

L^1 er $-CH_2-$ eller -C(O)-;

L^2 er -C(O)-;

R^1 er -Cl, $-CH_3$, eller syklopropyl;

R^2 er -Cl eller $-CH_3$;

hver R^3 er uavhengig H, -F, -Br, -Cl, -CN, $-CH_3$, $-CF_3$, $-OCH_3$, $-OCHF_2$, $-OCF_3$, $-CONHCH_3$, $-CON(CH_3)_2$, $-NHCOCH_3$, syklopropyl, eller morfolinyl;

R^4 er valgfritt substituert (C_1-C_6)alkyl, $-NH-CH_2-$ valgfritt substituert tetrahydro-2H-pyranyl, -NH-valgfritt substituert sykloheksyl, valgfritt substituert azabisyklo[2,2,1]heptanyl, valgfritt substituert 3-azabisyklo[3,1,0]heksanyl, valgfritt substituert azaspiro[3,3]heptanyl, valgfritt substituert azetidinyl, valgfritt substituert syklobutyl, valgfritt substituert sykloheksyl, valgfritt substituert syklopentyl, valgfritt substituert 1,4-diazepanyl, valgfritt substituert morfolinyl, valgfritt substituert 2-oxa-6-azaspiro[3,3]heptanyl, valgfritt substituert 2-oxa-7-azaspiro[3,5]nonanyl, valgfritt substituert 2-oxa-8-azaspiro[4,5]dekanyl, valgfritt substituert piperazinyl, valgfritt substituert piperidinyl, eller valgfritt substituert pyrrolidinyl.

9. Forbindelse ifølge krav 1, eller et farmasøytisk akseptabelt salt av samme, hvori:

W er C;

X er NR^a, hvori R^a er H eller $-CH_3$;

Y er CR^a, hvori R^a er H;

Z er N;

A er C;

E er C;

V er CR^3, hvori R^3 er H;

L^1 er forbundet med W;

L^1 er $-CH_2-$ eller -C(O)-;

L^2 er -C(O)-;

R^1 er -Cl;

R^2 er -Cl;

hver R^3 er uavhengig H, $-CH_3$, eller $-CF_3$; og

R^4 er valgfritt substituert morfolinyl, valgfritt substituert piperazinyl, eller valgfritt substituert piperidinyl.

10. Forbindelse ifølge krav 1, eller et farmasøytisk akseptabelt salt av samme, hvori:

W er CR^a, hvori R^a er H;

X er O eller NR^a, hvori R^a er H eller $-CH_3$;

Y er C;

Z er CR^3, hvori R^3 er H eller $-CF_3$;

A er C;

E er C;

V er CR^3, hvori R^3 er H;

L^1 er forbundet med Y;

L^1 er $-CH_2-$;

L^2 er -C(O)-;

R^1 er -Cl;

R^2 er -Cl;

hver R^3 er uavhengig H, $-CH_3$, $-CF_3$, eller $-OCF_3$; og

R^4 er valgfritt substituert piperidinyl.

11. Forbindelse ifølge krav 10 eller et farmasøytisk akseptabelt salt av samme, hvori det valgfritt substituerte piperidinyl er valgfritt substituert med $-CH_3$, -COOH, $-CH_2COOH$, - $CH_2CO_2CH_3$, eller - $CO_2CH_2CH_3$.

12. Forbindelse ifølge krav 1, hvori forbindelsen er:



A1 ,



BM-1 ,



A1-1 ,



BN ,



A1-2 ,



BN-1 ,



A1-3 ,



BN-3 ,



A1-4 ,



BN-4 ,



A1-5 ,



BN-5 ,



A1-6 ,



BN-6 ,



A1-7 ,



BN-7 ,



A1-8 ,



BN-8 ,



A1-9 ,



BN-9 ,



A1-10 ,



BN-10 ,



A1-11 ,



BN-11 ,



B

,



BN-12

,



B-1

,



BN-13

,



B-2

,



BN-14

,



B-3

,



BN-15

,



B-4

,



BN-16

,



B-5

,



BN-17

,



B-6



BO



B-7



BP



B-8



BQ



B-9



BR



B-10



BS



B-11



BT



B-12

,



BU

,



B-13

,



BV

,



B-14

,



BY

,



B-15

,



BZ

,



B-16

,



CA

,



B-17



CB



B-18



CC



B-19



CD



B-21



CE



B-22



CF



B-23

,



CG

,



B-24

,



CH

,



B-26

,



CI

,



B-27

,



CJ

,



B.2

,



CK

,



B.2

,



CL

,



C



CL-1



D



CL-2



D-1



CM



D-2



CM1



D-3



CO



E



CP



F



CQ



F1-1



CR



F1-2



CS



F1-3



CT



G



G1



H



I



J



L



CT-1



CT-2



CT-3



CT-4



CT-5



CT-6



L-1



CT-7



L-2



CT-8



L-3



CT-9



L-4



CT-10



L-5



CT-11



M ,



CT-12 ,



N ,



CU ,



O ,



CV ,



P ,



CV-1 ,



R ,



CV-2 ,



S ,



CV-3 ,



T ,



U ,



V ,



AA ,



AA-1 ,



AA-2 ,



CV-4 ,



CV-5 ,



CV-6 ,



CW ,



CY ,



CZ ,



AA-3 ,

CZ-1 ,



AA-4 ,



CZ-2 ,



AA-5 ,



CZ-3 ,



AA-6 ,



CZ-1A ,



AA-7 ,



DA ,



AA-8

,



DB

,



AA-9

,



DC

,



AA-10

,



DD

,



AA-11

,



DD-1

,



AA-12

,



DE

,



AA-13

,



DF

,



AA-14

,



DG

,



AA-15

,



DH

,



AA-16

,



DH-1

,



AA-17

,



DH-2

,



AA-18

,



DH1-1

,



AA-19

,



DH1-2

,



AA-20

,



DI

,



AA-21

,



DJ

,



AA-25

,



DJ-1

,



AA-26



DJ-2



AA-27



DJ-3



AA-28



DJ1-1



AA-29



DJ1-2



AA-30



DJ1-3



AA-31 ,



DK ,



AA-32 ,



DL ,



AA-33 ,



DM ,



AA-34 ,



DN ,



AA-35 ,



DO ,



AA-36

,



DP

,



AA-38

,



DP-1

,



AA-39

,



DP-2

,



AA-40

,



DP-3

,



AB

,



DQ

,



AC

,



DR

,



AD

,



DS

,



AE

,



DT

,



AM

,



DU

,



AM-1

,



DU-1

,



AM-2

,



DU-2

,



AM-3

,



DU1-1

,



AN

,



DU1-2

,



AN-1

,



DV

,



AN-2

,



DW

,



AN-3

,



DX

,



AN-4

,



AN-5

,



AN-6

,



AO

,



AP

,



AP-1

,



DY

,



EA

,



EB

,



EC

,



ED

,



EE

,



AP-2

,



EF

,



AP-3

,



EG

,



AP-4

,



EG-1

,



AP-5

,



EG-2

,



AP-6

,



EH

,



AP-7 ,



EH-1 ,



AP-8 ,



EI ,



AQ ,



EI-1 ,



AQ-1 ,



EI-2 ,



AQ-2 ,



EI-3 ,



AQ-3

,



EI-4



AQ-4

,



EI-5

,



AQ-5

,



EI-7

,



AS

,



EJ

,



AT

,



EJ-1

,



AV

,



EJ-2

,



AW ,



EK ,



AX ,



EL ,



AY ,



EL-1 ,



AZ ,



EM ,



BA ,



EN ,



BB

,



EO

,



BC

,



EP

,



BD

,



EQ

,



BE

,



ER

,



BF

,



ES

,



BF-1

,



ET

,



BF-2

,



BF-3

,



BF-4

,



BF-5

,



BF-6

,



BG

,



EU

,



EV

,



EW

,



EX

,



EY

,



EZ

,



BH ,



FA ,



BH-1 ,



FB ,



BH-2 ,



FC ,



BJ ,



FD ,



BJ-1 ,



FE ,



BJ-2 ,



FE-2 ,



BJ-3 ,



FE-3 ,



BJ-4

,



FE-4 ,



BJ-5 ,



FF ,



BJ-6 ,



FF-1 ,



BJ-7

5 ,



FF-2 ,



BJ-8

,



FG

,



BJ-9

,



FH

,



BJ-10

,



FI

,



BJ-11

,



FI-1

,



BJ-12

,



FJ

,



BJ-13

,



FK

,



BJ-14

,



FL

,



BJ-15

,



FM

,



BJ-16

,



FN

,



BJ-17

,



FO

,



BJ-18

,



FP

,



BJ-19

,



FQ

,



BJ-21 ,



FR ,



BJ-23 ,



FS ,



BJ-25 ,



FT ,



BJ-27 ,



FT-1 ,



BJ-28 ,



FT-3 ,



BJ-29 ,



FU ,



BJ-30

,



FW

,



BJ-31

,



FX

,



BJ-32

,



FY

,



BJ-33

,



FZ

,



BJ-34

,



GA

,



BJ-35

,



GB

,



BJ-36 ,



GC ,



BJ-37 ,



GD ,



BJ-38 ,



GE ,



BJ-39 ,



GF ,



BJ-40 ,



GG ,



BJ-41 ,



GH ,



BJ-42 ,



GI ,



BJ-43 ,



GJ ,



BK ,



GK ,



BL ,



GL ,



BM ,



GN ,

eller et farmasøytisk akseptabelt salt av samme.

13. Forbindelse ifølge krav 12, hvori forbindelsen er:



B.

14. Forbindelse ifølge krav 12, hvori forbindelsen er et farmasøytisk akseptabelt salt av:



B.

15. Forbindelse ifølge krav 12, hvori forbindelsen er:



DP.

16. Forbindelse ifølge krav 12, hvori forbindelsen er et farmasøytisk akseptabelt salt av:



DP.

17. Forbindelse ifølge krav 12, hvori forbindelsen er:



EI-5.

18. Forbindelse ifølge krav 12, hvori forbindelsen er et farmasøytisk akseptabelt salt av:



EI-5.

19. Forbindelse ifølge krav 12, hvori forbindelsen er:



FQ.

20. Forbindelse ifølge krav 12, hvori forbindelsen er et farmasøytisk akseptabelt salt av:



FQ.

21. Farmasøytisk blanding som omfatter:

(i) en forbindelse ifølge ett av kravene 1 til 11, eller et farmasøytisk akseptabelt salt av samme, eller

(ii) en forbindelse ifølge krav 12 eller et farmasøytisk akseptabelt salt av samme, eller

(iii) en forbindelse ifølge ett av kravene 13, 15, 17, eller 19, eller

(iv) et farmasøytisk akseptabelt salt av en forbindelse ifølge ett av kravene 14, 16, 18, eller 20,

og ett eller flere farmasøytisk akseptable hjelpestoffer.